Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Livea vs SnagRx

Livea
Graded #115

Higher grade

vs+11.800000000000004
SnagRx
Graded #387

Lower grade

The verdict

Livea takes it — 69.7/100 to 57.9/100.

Livea grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Livea is a physician-supervised medical weight loss clinic founded in 2011 with 8 clinics in MN and WI, plus telehealth in MN, WI, Iowa, and Florida.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLivea +18
54
36
Dose & formulationEven
64
64
Clinical oversightLivea +17
93
76
Labs & monitoringLivea +20
73
53
FulfillmentLivea +8
79
71
Contract termsEven
55
55
Livea · left barSnagRx · right bar

The numbers

MetricLiveaSnagRx
WeighScore69.7/10057.9/100
GradeCC
Scorecard rank#115#387
Semaglutide$99/mo (plus a separate fee, compounded)$299/mo (starting dose, compounded)
Tirzepatide$199/mo (compounded)$399/mo (starting dose, compounded)
Coverage4 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Livea

Graded #115 · C

Strengths

  • LegitScript certified; physician-owned Livea Medical PLLC; Medical Director Dr. Paul Olson, internal medicine/nephrology, 40 years experience
  • Compounded sema from $99/mo and tirz from $199/mo — significantly cheaper than brand Ozempic/Wegovy ($1,000+/mo self-pay)
  • Comprehensive program: InBody scans, registered dietitian nutrition counseling, health coaching, and regular provider check-ins included
  • 15+ years established (founded 2011); 50,000+ clients served; voted Minnesota's Best Weight Loss Program 5 consecutive years
  • Medications shipped to door; same-day consultations; in-person or telehealth; typically HSA/FSA eligible

Where it loses points

  • Telehealth limited to 4 states only (MN, WI, IA, FL) — unavailable to most of the US; primarily a regional clinic network
  • Pricing ambiguous: $69/mo program fee plus separate medication cost ($99/mo sema) may bring GLP-1 total to ~$168/mo
  • Compounded tirzepatide availability uncertain — FDA announced shortage end in 2026; access subject to eligibility
  • Labs (bloodwork) not explicitly included in any published program tier; confirmed at consultation only
  • Strong MN/WI clinic focus; telehealth reach into IA and FL is newer and less established than core markets
SnagRx

Graded #387 · C

Strengths

  • Compounded semaglutide ($99/mo) and tirzepatide ($149/mo) on launch discount, flat-priced at every dose
  • Names four partner pharmacies in Terms (RedRock, Health Warehouse, Precision Compounding, Triad Rx)
  • Available in all 50 states plus Washington D.C. per Terms
  • Telemed visit, prescription and free 1-2 day shipping included; no insurance or membership
  • Cancel anytime; full refund if disqualified by the medical provider

Where it loses points

  • Headline $99/$149 prices are discounted from $299/$399 standard; a countdown timer pressures signup
  • No brand-name Wegovy/Zepbound/Mounjaro/Ozempic - compounded injectable only
  • Refunds only available before medication is ordered; all sales otherwise final
  • Binding JAMS arbitration under Delaware law; class-action waiver

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard